Cargando…
Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients
PURPOSE: Extension of adjuvant endocrine therapy (ET) reduces the risk of recurrence in women diagnosed with ER-positive breast cancers, but a significant benefit is unlikely to happen to all individual patients. This study is aimed at evaluating the ability of different clinical late distant recurr...
Autores principales: | Villasco, Andrea, Accomasso, Francesca, D’Alonzo, Marta, Agnelli, Francesca, Sismondi, Piero, Biglia, Nicoletta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354987/ https://www.ncbi.nlm.nih.gov/pubmed/33939116 http://dx.doi.org/10.1007/s12282-021-01258-5 |
Ejemplares similares
-
Surgery after Neoadjuvant Chemotherapy: A Clip-Based Technique to Improve Surgical Outcomes, a Single-Center Experience
por: Minella, Carola, et al.
Publicado: (2022) -
Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Rosso, Roberta, et al.
Publicado: (2023) -
The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study
por: Villasco, Andrea, et al.
Publicado: (2021) -
Current Evidence of the Oncological Benefit-Risk Profile of Hormone Replacement Therapy
por: D’Alonzo, Marta, et al.
Publicado: (2019) -
Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2020)